Antimalarial Drug Resistance With Assessment of Transmission Blocking Activity
Status:
Suspended
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a two-arm, open label Treatment Study comparing the efficacy, safety, tolerability
and pharmacokinetics of a three-day course of Dihydroartemisinin-Piperaquine (DP) with or
without single-dose primaquine in patients with uncomplicated Plasmodium falciparum malaria.
On the last day of DP therapy, volunteers will be randomized to receive either a single 45 mg
dose of primaquine (PQ) or DP treatment only (no primaquine).
Phase:
N/A
Details
Lead Sponsor:
David Saunders
Collaborators:
National Centre for Parasitology, Entomology and Malaria Control, Cambodia Royal Cambodian Armed Forces US Department of Defense Armed Forces Health Surveillance Center